MX347805B - Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico. - Google Patents
Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.Info
- Publication number
- MX347805B MX347805B MX2013004753A MX2013004753A MX347805B MX 347805 B MX347805 B MX 347805B MX 2013004753 A MX2013004753 A MX 2013004753A MX 2013004753 A MX2013004753 A MX 2013004753A MX 347805 B MX347805 B MX 347805B
- Authority
- MX
- Mexico
- Prior art keywords
- immunodiagnostics
- fviii
- immune tolerance
- tolerance induction
- peptides
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000006058 immune tolerance Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 4
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 3
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 2
- 208000009292 Hemophilia A Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000009093 first-line therapy Methods 0.000 abstract 1
- 102000057593 human F8 Human genes 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000009256 replacement therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
La presente invención se refiere a péptidos que pueden usarse para reducir la respuesta inmune al FVIII o para inducir tolerancia al FVIII humano en pacientes afectados, por ejemplo, por hemofilia A. Los péptidos también pueden usarse con fines de inmunodiagnostico, para detectar células T CD4+ con especificidad por el FVIII y monitorear los pacientes con hemofilia A durante las terapias de remplazo y durante las terapias de inducción de tolerancia inmune.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40740210P | 2010-10-27 | 2010-10-27 | |
| US201161467894P | 2011-03-25 | 2011-03-25 | |
| US201161502476P | 2011-06-29 | 2011-06-29 | |
| PCT/US2011/058165 WO2012058480A1 (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004753A MX2013004753A (es) | 2013-09-13 |
| MX347805B true MX347805B (es) | 2017-05-15 |
Family
ID=45349271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004753A MX347805B (es) | 2010-10-27 | 2011-10-27 | Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8969524B2 (es) |
| EP (2) | EP2632479B1 (es) |
| JP (2) | JP6122780B2 (es) |
| KR (2) | KR102222864B1 (es) |
| CN (2) | CN103298482B (es) |
| AR (1) | AR083586A1 (es) |
| AU (2) | AU2011319747C1 (es) |
| BR (1) | BR112013010362A2 (es) |
| CA (1) | CA2815239C (es) |
| DK (1) | DK2632479T3 (es) |
| EA (1) | EA034494B1 (es) |
| ES (2) | ES2639039T3 (es) |
| HK (1) | HK1215442A1 (es) |
| MX (1) | MX347805B (es) |
| NZ (2) | NZ703514A (es) |
| PL (2) | PL2632479T3 (es) |
| PT (1) | PT2632479T (es) |
| SG (2) | SG10201600656WA (es) |
| TW (3) | TWI580430B (es) |
| WO (1) | WO2012058480A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100256062A1 (en) | 2004-12-06 | 2010-10-07 | Howard Tommy E | Allelic Variants of Human Factor VIII |
| BR112015010625B1 (pt) * | 2012-11-12 | 2023-03-07 | Apitope International Nv | Peptídeos |
| US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
| EP2968499A4 (en) * | 2013-03-15 | 2016-11-30 | Haplomics Inc | COMPOSITIONS AND METHODS FOR THE IMMUNO-TOLERANCE INDUCTION FOR FACTOR VIII SPATIAL THERAPIES IN PERSONS WITH HEMOPHILIA A |
| JP6488376B2 (ja) * | 2014-06-12 | 2019-03-20 | ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ | 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬 |
| AU2016212158B2 (en) * | 2015-01-26 | 2021-06-03 | Allogene Therapeutics, Inc. | mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells |
| BR112018070463A8 (pt) | 2016-04-15 | 2022-08-30 | Baxalta GmbH | Método e aparelho para prover um regime farmacocinético de dosagem de fármaco |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2482926A1 (en) * | 2002-04-18 | 2003-10-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified factor viii |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| WO2005114221A2 (en) * | 2004-05-21 | 2005-12-01 | The Institute For Systems Biology | Compositions and methods for quantification of serum glycoproteins |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| KR101423344B1 (ko) | 2006-01-04 | 2014-07-30 | 백스터 인터내셔널 인코포레이티드 | 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법 |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| US7673687B2 (en) | 2007-12-05 | 2010-03-09 | Halliburton Energy Services, Inc. | Cement compositions comprising crystalline organic materials and methods of using same |
| DE202007017320U1 (de) | 2007-12-07 | 2008-02-28 | Dittmann, Ludwig | Vorrichtung zur Raumbeduftung |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| WO2009099991A2 (en) | 2008-01-31 | 2009-08-13 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| BRPI0921429B1 (pt) | 2008-11-07 | 2022-07-12 | Takeda Pharmaceutical Company Limited | Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável |
-
2011
- 2011-10-27 TW TW100139078A patent/TWI580430B/zh active
- 2011-10-27 PT PT117968461T patent/PT2632479T/pt unknown
- 2011-10-27 TW TW105138248A patent/TW201708251A/zh unknown
- 2011-10-27 KR KR1020197032106A patent/KR102222864B1/ko not_active Expired - Fee Related
- 2011-10-27 NZ NZ703514A patent/NZ703514A/en unknown
- 2011-10-27 MX MX2013004753A patent/MX347805B/es active IP Right Grant
- 2011-10-27 NZ NZ609474A patent/NZ609474A/en unknown
- 2011-10-27 PL PL11796846T patent/PL2632479T3/pl unknown
- 2011-10-27 EP EP11796846.1A patent/EP2632479B1/en active Active
- 2011-10-27 TW TW106113613A patent/TW201730205A/zh unknown
- 2011-10-27 KR KR1020137013231A patent/KR102040867B1/ko active Active
- 2011-10-27 ES ES11796846.1T patent/ES2639039T3/es active Active
- 2011-10-27 EP EP17167928.5A patent/EP3260132B1/en active Active
- 2011-10-27 EA EA201390617A patent/EA034494B1/ru not_active IP Right Cessation
- 2011-10-27 WO PCT/US2011/058165 patent/WO2012058480A1/en not_active Ceased
- 2011-10-27 ES ES17167928T patent/ES2912455T3/es active Active
- 2011-10-27 SG SG10201600656WA patent/SG10201600656WA/en unknown
- 2011-10-27 CN CN201180063117.9A patent/CN103298482B/zh active Active
- 2011-10-27 CA CA2815239A patent/CA2815239C/en active Active
- 2011-10-27 US US13/283,452 patent/US8969524B2/en active Active
- 2011-10-27 DK DK11796846.1T patent/DK2632479T3/en active
- 2011-10-27 AU AU2011319747A patent/AU2011319747C1/en active Active
- 2011-10-27 BR BR112013010362A patent/BR112013010362A2/pt not_active Application Discontinuation
- 2011-10-27 PL PL17167928.5T patent/PL3260132T3/pl unknown
- 2011-10-27 JP JP2013536845A patent/JP6122780B2/ja not_active Expired - Fee Related
- 2011-10-27 CN CN201510431485.4A patent/CN104926947A/zh active Pending
- 2011-10-27 SG SG2013028733A patent/SG189914A1/en unknown
- 2011-10-28 AR ARP110103988A patent/AR083586A1/es not_active Application Discontinuation
-
2015
- 2015-01-23 US US14/604,622 patent/US9512198B2/en active Active
-
2016
- 2016-03-22 HK HK16103339.6A patent/HK1215442A1/zh unknown
- 2016-04-06 AU AU2016202155A patent/AU2016202155B2/en active Active
- 2016-11-02 US US15/341,936 patent/US20170267743A1/en not_active Abandoned
- 2016-11-29 JP JP2016230723A patent/JP2017095463A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347805B (es) | Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico. | |
| MX366090B (es) | Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. | |
| IN2012DN06309A (es) | ||
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| MX2015006491A (es) | Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas. | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| NZ711373A (en) | Fragments of p97 and uses thereof | |
| EP2889371A4 (en) | BACTEROIDES CECT 7771 AND USE THEREOF IN THE PREVENTION AND TREATMENT OF OVERWEIGHT, FAT SUPPORT AND METABOLIC AND IMMUNOLOGICAL CHANGES | |
| AU334908S (en) | Glove for touchscreen use | |
| MX342716B (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| IN2014KN02830A (es) | ||
| SG10201803778PA (en) | Treatment for rheumatoid arthritis | |
| GB201118201D0 (en) | Novel peptides | |
| GB201210686D0 (en) | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level | |
| NZ631639A (en) | Methods and compositions for treating and diagnosing acute myocardial infarction | |
| EP2528939A4 (en) | RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH | |
| CY1123049T1 (el) | Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο για χρηση σε ανθρωπους | |
| EP2566502A4 (en) | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION | |
| MX362664B (es) | Antagonistas peptídicos del receptor de vasopresina 2. | |
| WO2012009640A3 (en) | B cell depletion for central nervous system injuries and methods and uses thereof | |
| EA201992559A1 (ru) | Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики | |
| GB201102090D0 (en) | Antigenic polypeptide | |
| Bakken | Vinik appointed professor emeritus in anesthesiology | |
| AU345482S (en) | Alu' sling cover dining chair | |
| UA56500U (en) | Myotonometer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: BAXALTA INCORPORATED |
|
| FG | Grant or registration |